Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

Karina Verma, Andrew Staron, Luke Zheng, Gheorghe Doros, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 6762.

https://doi.org/10.1182/blood-2023-179597

Published: 2023

Journal Articles

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H Connors, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 155.

https://doi.org/10.1182/blood-2021-151804

Published: 2021

Journal Articles

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

Andrew Staron, Lawreen H Connors, PhD, Luke Zheng, BS, Gheorghe Doros, PhD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 51.

https://doi.org/10.1182/blood-2020-139751

Published: 2020

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

https://doi.org/10.1182/blood-2019-124980

Published: 2019

Journal Articles

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis

Brian Lilleness, Frederick L. Ruberg, Roberta Mussinelli, Gheorghe Doros, Vaishali Sanchorawala

Blood (2019) 133 (3): 215–223.

https://doi.org/10.1182/blood-2018-06-858951

Published: 2019

Journal Articles

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation

Sabrina Browning, Karen Quillen, J. Mark Sloan, Gheorghe Doros, Shayna Sarosiek, Vaishali Sanchorawala

Blood (2017) 130 (11): 1383–1386.

https://doi.org/10.1182/blood-2017-06-788729

Published: 2017

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, Vaishali Sanchorawala

Blood (2012) 120 (22): 4445–4446.

https://doi.org/10.1182/blood-2012-09-457341

Published: 2012

Journal Articles

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Gheorghe Doros, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 1873.

https://doi.org/10.1182/blood.V120.21.1873.1873

Published: 2012

Journal Articles

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, J. Mark Sloan, Kathleen T. Finn, Gheorghe Doros, Joan Blade, Martha Skinner

Blood (2011) 118 (16): 4346–4352.

https://doi.org/10.1182/blood-2011-01-330738

Published: 2011

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

Journal Articles

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Vaishali Sanchorawala, Kathleen T. Finn, Salli Fennessey, Anthony Shelton, Gheorghe Doros, Jerome B. Zeldis, David C. Seldin

Blood (2010) 116 (11): 1990–1991.

https://doi.org/10.1182/blood-2010-07-295485

Published: 2010

Journal Articles

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Vaishali Sanchorawala, Martha Skinner, Karen Quillen, Kathleen T. Finn, Gheorghe Doros, David C. Seldin

Blood (2007) 110 (10): 3561–3563.

https://doi.org/10.1182/blood-2007-07-099481

Published: 2007

NARROW

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only